Antibody to hepatitis C virus in thalassemia patients.

I. Isahak, R. Baharin, A. S. Hakim, M. Abu Bakar, E. George

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    A specific enzyme immunoassay (EIA) for the diagnosis of hepatitis C virus (HCV) infection was developed by recombinant DNA technology. Abbott HCV EIA was used to detect antibody to HCV (anti-HCV) in non-transfused and multiply-transfused thalassemia patients. None of 11 non-transfused patients had anti-HCV but 3 of 52 (5.8%) multiply-transfused patients had anti-HCV. This study showed that the prevalence rate of HCV infection is low in thalassemia patients. However, it is still important to identify hepatitis C virus infected patients in high risk groups because hepatitis C is associated with chronic hepatitis, cirrhosis and hepatocellular carcinoma.

    Original languageEnglish
    Pages (from-to)85-87
    Number of pages3
    JournalThe Malaysian journal of pathology
    Volume15
    Issue number1
    Publication statusPublished - Jun 1993

    Fingerprint

    Hepatitis C Antibodies
    Thalassemia
    Hepacivirus
    Virus Diseases
    Immunoenzyme Techniques
    Recombinant DNA
    Chronic Hepatitis
    Hepatitis C
    Hepatocellular Carcinoma
    Fibrosis
    Cross-Sectional Studies
    Technology

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Isahak, I., Baharin, R., Hakim, A. S., Abu Bakar, M., & George, E. (1993). Antibody to hepatitis C virus in thalassemia patients. The Malaysian journal of pathology, 15(1), 85-87.

    Antibody to hepatitis C virus in thalassemia patients. / Isahak, I.; Baharin, R.; Hakim, A. S.; Abu Bakar, M.; George, E.

    In: The Malaysian journal of pathology, Vol. 15, No. 1, 06.1993, p. 85-87.

    Research output: Contribution to journalArticle

    Isahak, I, Baharin, R, Hakim, AS, Abu Bakar, M & George, E 1993, 'Antibody to hepatitis C virus in thalassemia patients.', The Malaysian journal of pathology, vol. 15, no. 1, pp. 85-87.
    Isahak I, Baharin R, Hakim AS, Abu Bakar M, George E. Antibody to hepatitis C virus in thalassemia patients. The Malaysian journal of pathology. 1993 Jun;15(1):85-87.
    Isahak, I. ; Baharin, R. ; Hakim, A. S. ; Abu Bakar, M. ; George, E. / Antibody to hepatitis C virus in thalassemia patients. In: The Malaysian journal of pathology. 1993 ; Vol. 15, No. 1. pp. 85-87.
    @article{1f09dbbbf94c44f2978c3b23365c81f7,
    title = "Antibody to hepatitis C virus in thalassemia patients.",
    abstract = "A specific enzyme immunoassay (EIA) for the diagnosis of hepatitis C virus (HCV) infection was developed by recombinant DNA technology. Abbott HCV EIA was used to detect antibody to HCV (anti-HCV) in non-transfused and multiply-transfused thalassemia patients. None of 11 non-transfused patients had anti-HCV but 3 of 52 (5.8{\%}) multiply-transfused patients had anti-HCV. This study showed that the prevalence rate of HCV infection is low in thalassemia patients. However, it is still important to identify hepatitis C virus infected patients in high risk groups because hepatitis C is associated with chronic hepatitis, cirrhosis and hepatocellular carcinoma.",
    author = "I. Isahak and R. Baharin and Hakim, {A. S.} and {Abu Bakar}, M. and E. George",
    year = "1993",
    month = "6",
    language = "English",
    volume = "15",
    pages = "85--87",
    journal = "Malaysian Journal of Pathology",
    issn = "0126-8635",
    publisher = "Malaysian Society of Pathologists",
    number = "1",

    }

    TY - JOUR

    T1 - Antibody to hepatitis C virus in thalassemia patients.

    AU - Isahak, I.

    AU - Baharin, R.

    AU - Hakim, A. S.

    AU - Abu Bakar, M.

    AU - George, E.

    PY - 1993/6

    Y1 - 1993/6

    N2 - A specific enzyme immunoassay (EIA) for the diagnosis of hepatitis C virus (HCV) infection was developed by recombinant DNA technology. Abbott HCV EIA was used to detect antibody to HCV (anti-HCV) in non-transfused and multiply-transfused thalassemia patients. None of 11 non-transfused patients had anti-HCV but 3 of 52 (5.8%) multiply-transfused patients had anti-HCV. This study showed that the prevalence rate of HCV infection is low in thalassemia patients. However, it is still important to identify hepatitis C virus infected patients in high risk groups because hepatitis C is associated with chronic hepatitis, cirrhosis and hepatocellular carcinoma.

    AB - A specific enzyme immunoassay (EIA) for the diagnosis of hepatitis C virus (HCV) infection was developed by recombinant DNA technology. Abbott HCV EIA was used to detect antibody to HCV (anti-HCV) in non-transfused and multiply-transfused thalassemia patients. None of 11 non-transfused patients had anti-HCV but 3 of 52 (5.8%) multiply-transfused patients had anti-HCV. This study showed that the prevalence rate of HCV infection is low in thalassemia patients. However, it is still important to identify hepatitis C virus infected patients in high risk groups because hepatitis C is associated with chronic hepatitis, cirrhosis and hepatocellular carcinoma.

    UR - http://www.scopus.com/inward/record.url?scp=0027605555&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0027605555&partnerID=8YFLogxK

    M3 - Article

    VL - 15

    SP - 85

    EP - 87

    JO - Malaysian Journal of Pathology

    JF - Malaysian Journal of Pathology

    SN - 0126-8635

    IS - 1

    ER -